Target intelligence / Profile preview

Syndecan-binding protein 1 (SDCBP)

Target
SDCBP
Molecular classification
Adaptor protein, Scaffold protein, PDZ domain-containing protein
01

Overview

Syndecan-binding protein 1 (SDCBP), also known as Syntenin-1 or MDA-9, is a multifunctional PDZ domain-containing adaptor protein that serves as a critical scaffold for various cellular processes, including exosome biogenesis, transmembrane protein trafficking, and signal transduction (UniProt O00560). It facilitates the assembly of signaling complexes by interacting with the cytoplasmic tails of syndecans, tetraspanins, and growth factor receptors such as EGFR and TGF-βR1 (GeneCards). In oncology, SDCBP is frequently overexpressed and acts as a pro-metastatic factor, promoting tumor cell migration, invasion, and epithelial-mesenchymal transition (EMT) through the activation of FAK/Src, MAPK, and NF-κB pathways (PubMed: 26291527). It also plays a role in immune evasion by upregulating PD-L1 and modulating the tumor microenvironment to favor cancer progression (PNAS, 2021). Beyond cancer, SDCBP is involved in neurodevelopmental processes like synaptic transmission and has been implicated in inflammatory responses and heart failure progression (Frontiers in Immunology, 2022). Given its central role in cancer dissemination and exosome-mediated communication, SDCBP is an emerging therapeutic target, with several small-molecule inhibitors targeting its PDZ domains, such as PDZ1i and SYNTi, currently under preclinical investigation (MedChemExpress).

Other names
Syntenin-1Melanoma differentiation-associated protein 9MDA-9Pro-TGF-alpha cytoplasmic domain-interacting protein 18TACIP18Scaffold protein Pbp1
02

Mechanism of action

Inhibition of PDZ domain-mediated protein-protein interactions to disrupt oncogenic signaling and exosome secretion.

03

Biological functions

Signal transductionExosome biogenesisProtein traffickingCell adhesionImmune responseCell proliferationCytoskeletal organizationSynaptic transmission
04

Disease associations

CancerInflammationCardiovascular disease
05

Safety considerations

Potential disruption of synaptic transmissionPotential impairment of B-cell developmentPotential interference with normal tissue repair and wound healing
06

Interacting drugs

PDZ1i (113B7)

3 more in the full profile.

07

Biomarkers

SDCBP protein expressionSDCBP mRNA levels

Beyond the preview

Go deeper on Syndecan-binding protein 1 (SDCBP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Syndecan-binding protein 1 (SDCBP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call